月旦知識庫
  1. 熱門:
 
首頁 臺灣期刊   法律   公行政治   醫學   財經   社會學   教育   其他 大陸期刊   核心   非核心 DOI文章
本站僅提供期刊文獻檢索。【月旦知識庫】是否收錄該篇全文,敬請【登入】查詢為準。
最新【購點活動】
篇名
微小核酸-29c於乳癌、子宮頸癌、子宮內膜癌和卵巢癌之預後價值
並列篇名
Prognostic Value of MiR-29c in Breast, Cervical, Endometrial, and Ovarian Cancer
作者 Jimmy Chun-Min Su (Jimmy Chun-Min Su)林烘煜 (Hung-Yu Lin)
中文摘要

乳癌(BC)和婦科癌包括子宮頸癌(CC),子宮內膜癌(EC)和卵巢癌 (OC)是全球主要的死亡原因。在台灣,乳癌和婦科癌症是女性罹患癌症的最高 死亡率。微小核酸(miR)-29c 已知具有腫瘤調節作用。但是,miR-29c 在乳腺 癌和婦科癌症中的預後價值仍然不確定。在這項研究中,我們存取 UALCAN 以進 行《癌症基因組圖譜》(TCGA)數據挖掘,確定 miR-29c 表達水平是否可以用作 預測標記。研究調查 miR-29c 的表達水平,分析高表達和低表達 miR-29c 的患者 組之間的生存分析。miR-29c 表達在正常和 BC 腫瘤組織之間無統計學差異。帶有 HER2 陽性和三陰性的 BC(TNBC)的 miR-29c 表達水平低於管腔亞型。攜帶低表 達 miR-29c 的 BC 患者比那些高表達 miR-29c 的患者俱有更短的生存時間。miR-29c 表達在正常和 CC 腫瘤組織之間無統計學差異。第四期 CC 組織的 miR-29c 表達水 平低於第三期 CC 組織。值得注意的是,具有低表達 miR-29c 的 CC 患者的生存時 間短於具有高表達 miR-29c 的 CC 患者。關於 EC,miR-29c 表達在正常和 EC 腫瘤 組織之間表現出統計學差異。青年時期的 EC 組織顯示出比老年時期更高的 miR-29c 表達值。此外,與那些高表達 miR-29c 的 EC 患者相比,那些低表達 miR-29c 的 EC 患者的生存時間縮短。有趣的是,子宮癌惡性肉瘤(UCS)則是在較老患者表現量 高於年輕者,且 miR-29c 高表達量預測生存時間縮短。在 OC 中,年齡最大的人 群的 miR-29a 表達水平低於年輕人組。miR-29c 的低表達表明存活率低。我們得出 的結論是,低表達 miR-29c 可以預測 BC,CC,EC 和 OC 患者的不良生存率,在 UCS 則是高表達 miR-29c。

 

英文摘要

Breast cancer (BC) and gynecological cancers including cervical cancer (CC), endometrial cancer (EC), uterine carcinosarcomas (UCS), and ovarian cancer (OC) are a leading cause of death globally. In Taiwan, breast cancer and gynecological cancers account for the highest mortality in women suffering from cancer. The tumor- regulatory role of microRNA (miR)-29c has been reported. However, the prognostic value of miR-29c in breast cancer and gynecological cancers remains uncertain. In this study, we performed Cancer Genome Atlas (TCGA) data-mining via UALCAN to determine whether miR-29c expression levels can serve as a predictive marker. Expression levels of miR-29c were surveyed. Survival analysis between patient groups harboring high and low expression of miR-29c were analyzed. miR-29c expression showed no statistical difference between normal and BC tumor tissue. BC with HER2-positive and triple negative (TNBC) showed lower miR-29c expression levels than that of the luminal subtype. BC patients harboring low expression of miR-29c demonstrated shorter survival time than those with high expression of miR-29c. miR-29c expression showed no statistical difference between normal and CC tumor tissue. CC tissue of stage 4 had lower miR-29c expression levels than that of stage 3. Notably, CC patients harboring low expression of miR-29c demonstrated shorter survival time than those with high expression of miR-29c. With regard to EC, miR-29c expression exhibited a statistical difference between normal and EC tumor tissue. EC tissue from young aged patients showed higher value of miR-29c expression than that in older aged patients. Furthermore, EC patients harboring low expression of miR-29c presented reduced survival time as compared those harboring high expression of miR- 29c. Interestingly, we noted that another type of uterus cancer, uterine carcinosarcomas (UCS), expressed higher miR-29c levels in older aged patients and miR-29c high expression predicted reduced survival time.
In OC, miR-29a expression levels of the oldest cohort were lower than those of young groups. Low expression of miR-29c indicated poor survival rate. We conclude that low expression of miR-29c can predict poor survival rate in patients with BC, CC, EC, UCS, and OC.

 

起訖頁 068-079
關鍵詞 Breast cancerCervical cancerEndometrial cancerUterine carcinosarcomasOvarian cancerMicrorna-29cPrognostic biomarkers
刊名 秀傳醫學雜誌  
期數 202112 (20:2期)
出版單位 秀傳紀念醫院
該期刊-上一篇 ARES: Augmented Reality Echo-Guided Surgery
該期刊-下一篇 矯正單位和醫院間抗甲氧苯青黴素金黃色葡萄球菌在皮膚與軟組織感染之分子流行病學比較分析
 

新書閱讀



最新講座


優惠活動




讀者服務專線:+886-2-23756688 傳真:+886-2-23318496
地址:臺北市館前路28 號 7 樓 客服信箱
Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄